Roche Blocks Indian Trastuzumab; Says No Room For ''Uncertainty''
This article was originally published in Scrip
Executive Summary
Roche has moved to block Reliance Life Sciences Pvt Ltd's biosimilar version of its anticancer Herceptin (trastuzumab) in India citing "genuine" concern over the comparable safety and efficacy of the Indian firm's product.